Outcome MeasureDepression

SHAPS

Snaith-Hamilton Pleasure Scale

4 Papers in Blossom

About This Instrument

The SHAPS (Snaith-Hamilton Pleasure Scale) is a 14-item self-report scale measuring hedonic tone — the capacity to experience pleasure. Items assess pleasurable responses across four domains: interests and pastimes, social interaction, sensory experiences, and food and drink. Scores range from 0 to 14; higher scores indicate greater anhedonia. A score of ≥3 is commonly used as a clinical threshold. The SHAPS is used in depression research as a targeted measure of anhedonia, a core feature of major depressive disorder and a domain of particular interest in psychedelic trials.

Outcome Data Across Studies

Reported results for SHAPS across 4 studies with quantitative data.

Outcome data across 11 study arm–timepoint observations
SD
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)712Δ
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)9012Δ
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
2022Secondary
Psilocybin(experimental)019
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
2022Secondary
Psilocybin(experimental)119Δ
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
2022Secondary
Psilocybin(experimental)719Δ
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
2022Secondary
Psilocybin(experimental)9019Δ
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
2025Secondary
Psilocybin 25 mg(experimental)0Δ
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
2025Secondary
Placebo(inactive)0Δ
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
2026Secondary
Biphasic(experimental)0118.4
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
2026Secondary
Biphasic(experimental)2911-4.7Δ

Papers Using SHAPS

Quick Facts

Full Name
Snaith-Hamilton Pleasure Scale
Domain
Depression
Papers Indexed
4
Score Range
014
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures